Fresenius (NYSE:FMS) said today that it’s planning a stock buyback of up to $370 million worth of its own shares.
Shareholders in the German renal care giant said its shareholders approved the roughly 6-million-share buyback in May 2016. The €330 million repurchasing plan is slated to run from today through May 10, Fresenius said.
If fully exercised the buyback would result in the cancellation of about 1.6% of total FMS shares, the company said.
